Toshihiko Suzuki

Dr. Toshihiko Suzuki

Tokyo Bay Urayasu Ichikawa Medical Center
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
KYKana Yamamoto
Kana Yamamoto
TMTakahisa Mashiba
Takahisa Mashiba
KTKeisuke Takano
Keisuke Takano
TSToshihiko Suzuki
Toshihiko Suzuki
MKMasahiro Kami
Masahiro Kami
THTamae Hamaki
Tamae Hamaki
COVID-19 vaccines are the most critical measure for controlling the COVID-19 pandemic; however, we have little information on their complications. We experienced a case of a patient who developed hyperthyroidism complicated with atrial fibrillation and heart failure on the sixth day after the first dose of COVID-19 vaccination. This case report shows the importance of considering hyperthyroidism as a possible complication after COVID-19 vaccination.

14 December 2020 in Hypertension Research
Verified
Journal Article
Open access
PDF file
KKKoichi Kitamura
Koichi Kitamura
KHKoichi Hayashi
Koichi Hayashi
SIShinsuke Ito
Shinsuke Ito
YHYuiko Hoshina
Yuiko Hoshina
MSMasahiro Sakai
Masahiro Sakai
TSToshihiko Suzuki
Toshihiko Suzuki
Recent randomized trials demonstrating the beneficial effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in type 2 diabetes suggest that early reductions in eGFR upon initiation of SGLT2i therapy are associated with improved renal outcomes. Multiple concomitant medications, including antidiabetic and antihypertensive agents, are commonly used, however, which may modify the renal hemodynamic action of SGLT2is. Here we found that background treatment with metformin diminished the SGLT2i-induced reductions in eGFR after 3 months of SGLT2i therapy in patients with type 2 diabetes and hypertension (−2.29 ± 0.90 vs −5.85 ± 1.27 mL/min/1.73 m2 for metformin users (n = 126) and nonusers (n = 97), respectively). Other antidiabetic agents (DPP4 inhibitors, sulfonylureas and insulin) had no effect on the eGFR response to SGLT2is. Antihypertensive drugs, including calcium channel blockers (CCBs) and β blockers, did not affect the SGLT2i-induced changes in eGFR, whereas renin-angiotensin system inhibitors (RASis) tended to enhance this response (p = 0.059). Next, we evaluated the interaction between metformin and RASis in the eGFR responses to SGLT2is. Under no background treatment with RASis, metformin abrogated the eGFR response to SGLT2is, but this response was preserved when RASis had been given along with metformin (decreases of 0.75 ± 1.28 vs. 4.60 ± 1.15 mL/min/1.73 m2 in eGFR, p = 0.028). No interaction between metformin and insulin or between metformin and DPP4 inhibitors was observed. In conclusion, metformin blunts the SGLT2i-induced decrease in eGFR, but coadministration of RASis ameliorates this response. Furthermore, the inability of CCBs to modify the SGLT2i-induced reduction in eGFR suggests that the SGLT2i-induced renal microvascular action is mediated predominantly by postglomerular vasodilation rather than preglomerular vasoconstriction.

13 April 2023 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
SKShunsuke Kojima
Shunsuke Kojima
TNTatsuya Nakama
Tatsuya Nakama
TSToshihiko Suzuki
Toshihiko Suzuki
KOKotaro Obunai
Kotaro Obunai
HWHiroyuki Watanabe
Hiroyuki Watanabe

1 October 2018 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
SKShunsuke Kojima
Shunsuke Kojima
EHEiji Hiraoka
Eiji Hiraoka
JAJunya Arai
Junya Arai
YHYosuke Homma
Yosuke Homma
YNYasuhiro Norisue
Yasuhiro Norisue
HWHiroyuki Watanabe
Hiroyuki Watanabe
Background: A do-not-resuscitate (DNR) order is reportedly associated with a decrease in performance measures, but it should not be applied to noncardiopulmonary resuscitation procedures. Good performance measures are associated with improvement in heart failure outcomes. Aim: To analyze the influence of DNR order on performance measures of heart failure at our hospital, where lectures on DNR order are held every 3 months. Design: Retrospective cohort study. Methods: The medical report of patients with acute heart failure who were admitted between April 2013 and March 2015 were retrospectively analyzed. We collected demographic data, information on the presence or absence of DNR order within 24 hours of admission, and inhospital mortality. Performance measures of heart failure, including assessment of cardiac function and discharge prescription of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and beta-blocker for left ventricular systolic dysfunction and anticoagulant for atrial fibrillation, were collected and compared between groups with and without DNR orders. Results: In 394 total patients and 183 patients with left ventricular systolic dysfunction, 114 (30%) and 44 (24%) patients, respectively, had a DNR order. Patients with a DNR order had higher inhospital mortality. There were no significant differences between the two groups in terms of the four quality measures (left ventricular function assessment, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, and anticoagulant). Conclusion: DNR orders did not affect performance measures, but they were associated with higher inhospital mortality among acute heart failure patients.

1 January 2022 in Acute Medicine & Surgery
Verified
Journal Article
Open access
PDF file
KTKei Takehara
Kei Takehara
MMMichiko Mizobe
Michiko Mizobe
KEKeita Endo
Keita Endo
AMAkihiro Miyake
Akihiro Miyake
TSToshihiko Suzuki
Toshihiko Suzuki
HFHiraku Funakoshi
Hiraku Funakoshi
Background: We report a case of acute renal failure with loin pain and patchy renal ischemia after anaerobic exercise (ALPE) caused by sudden training resumption.Case presentation: A 19‐year‐old Asian man who was a college American football player presented with severe back pain, headache, and malaise. He developed acute kidney injury without myoglobinuria. Based on the typical medical history and symptoms, we made a diagnosis of ALPE. Symptoms improved within a few days, and serum creatinine levels improved after discharge. He resumed training, adjusting his load step by step.Conclusion: During the coronavirus disease 2019 pandemic, many athletes were unable to undergo adequate training. Long‐term de‐training leads to decreased various organ function and reduces the anaerobic threshold. Rapid resumption after prolonged de‐training may put individuals at risk of developing ALPE.

19 August 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
KTKeisuke Takano
Keisuke Takano
KHKoichi Hayashi
Koichi Hayashi
KKKoichi Kitamura
Koichi Kitamura
MKMutsuo Kanda
Mutsuo Kanda
KIKei Ito
Kei Ito
TSToshihiko Suzuki
Toshihiko Suzuki
Context: The fibrosis-4 (FIB-4) index is a noninvasive marker for liver fibrosis and is associated with the occurrence of diabetic kidney disease (DKD). Although sodium-glucose cotransporter-2 inhibitors (SGLT2is) are recognized to provide cardiovascular and renal benefits, the role of SGLT2is in regulating FIB-4 index and the subsequent effect on renal events remain unclear. Objective: This work aimed to clarify whether the FIB-4 index was associated with the development of DKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2 or new-onset macroalbuminuria) and whether the background treatment with other antidiabetic drugs modified the effects of SGLT2i on FIB-4 index and renal events. Methods: A retrospective cohort study was conducted that included 136 patients with type 2 diabetes mellitus who were newly given SGLT2is for 3 years. Results: Patients with a high FIB-4 index (≥1.3) at baseline exhibited a higher incidence of de novo DKD, compared to those with a lower FIB-4 index (<1.3). This association was ameliorated in patients whose FIB-4 index was decreased during the SGLT2i treatment. Finally, among the background therapies, metformin use was associated with a decrease in FIB-4 index and a lower cumulative incidence of de novo DKD. Conclusion: Elevated FIB-4 index at baseline is a potent predictor for developing DKD, and combination therapy with SGLT2is and metformin may enhance renal protection by modulating FIB-4 index.